The newest compound that is maximizing GLP-1’s efficacy!
For those of you that attended the Peptide Certification Course at A4M’s 26th Annual World Congress, congratulations on your certification! Seeing the industry grow and peptide knowledge being shared is inspiring and what IPS
Attendees heard two hours of lecture about GLP-1 and discussed in detail how to address the metabolic needs of their patients. Whether you attended the conference or not, we wanted to share with you the most recent metanalysis published in September on GLP-1s and the newest compound that might be the best addition to maximize efficacy!
Find out what else you should be using:
- Cardiovascular and microvascular outcomes of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled cardiovascular outcome trials with trial sequential analysis
Peptide education doesn’t have to end at the conference.
If you completed the peptide certification course, how are you going to stay up to date with the latest information? Our IPS members stay involved 24/7 and continue their education after conferences through our member-only forums, access to the latest full journal articles, bi-weekly webinars and much more.
Take a look at the attached link which mentions an oral medication which might enhance and make all your GLP-1 therapies more effective. How can you continue your education if you’re not getting access to information like this?
Join the discussion and continue your education when you become an IPS member today!
- DS-8500a, an Orally Available G Protein-Coupled Receptor 119 Agonist, Upregulates Glucagon-Like Peptide-1 and Enhances Glucose-Dependent Insulin Secretion and Improves Glucose Homeostasis in Type 2 Diabetic Rats.